Keryx Biopharma (KERX) Misses Q3 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. SPY
5. ANT
6. META
7. BA
8. INTC
9. JBLU
10. AAPL

Go back to Keryx Biopharma (KERX) Misses Q3 EPS by 11c

Keryx Biopharmaceuticals, Inc. Announces Third Quarter and Nine Month 2014 Financial Results

November 6, 2014 7:00 AM EST

NEW YORK, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease (the "Company" or "Keryx"), today announced its financial results for the third quarter ended September 30, 2014. At September 30, 2014, the Company had cash, cash equivalents, interest receivable and investment securities of $118.4 million, as compared to $55.7 million at December 31, 2013.

"The third quarter of 2014 was one of tremendous achievement at Keryx," said Ron Bentsur, Chief Executive Officer of Keryx. "With the approval of Ferric Citrate we are now... More